Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Eaddy

Interventional Pain Medicine Jacksonville, FL Medical Doctor

NPI 1154506376 CMS profile 279656

3750 San Jose Pl Ste 35, Ste 100, Jacksonville, FL 32257

Open in the dashboard

General payments

$27,968

390 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Eaddy of Jacksonville, FL is reported in the CMS Open Payments database as having received $27,968 across 390 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,008 18
2024 General $689 31
2023 General $4,810 37
2022 General $2,725 49
2021 General $14,016 129
2020 General $731 41
2019 General $3,989 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Eaddy
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Kenneth Eaddy were reported at $1,008. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Kenneth Eaddy Interventional Pain Medicine median Middle half National median
2019 $3,989 $684 $216–$2,079 $163
2020 $731 $382 $122–$1,109 $114
2021 $14,016 $552 $167–$1,554 $132
2022 $2,725 $605 $187–$1,924 $149
2023 $4,810 $671 $195–$1,915 $160
2024 $689 $684 $206–$1,837 $164
2025 $1,008 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spinal Simplicity, LLC $6,213 13 payments
  2. Boston Scientific Corporation $5,868 31 payments
  3. Alevio, LLC $3,365 3 payments
  4. Nevro Corp. $1,721 22 payments
  5. Flowonix Medical Incorporated $1,444 2 payments
  6. SPR Therapeutics, Inc $1,127 11 payments
  7. Collegium Pharmaceutical, Inc. $847 54 payments
  8. Amgen Inc. $736 29 payments
  9. Genesys Orthopedics Systems, L.L.C. $723 5 payments
  10. Nutech Spine, Inc. $705 2 payments
  11. Other $5,219 218 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,190 363 payments
  2. Travel and Lodging $9,463 21 payments
  3. Consulting Fee $6,775 2 payments
  4. Entertainment $1,377 1 payment
  5. Education $163 3 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $6,213 13 payments
  2. SPECTRA WAVEWRITER $4,530 9 payments
  3. SICURE SACROILIAC JOINT FUSION SYSTEM $3,365 3 payments
  4. Senza Spinal Cord Stimulation System $1,588 19 payments
  5. Prometra II $1,444 2 payments
  6. SPRINT PNS System $1,127 11 payments
  7. XTAMPZA $847 54 payments
  8. AIMOVIG $801 33 payments
  9. Superion $760 6 payments
  10. SACROILIAC JOINT FUSION SYSTEM $723 5 payments
  11. Other $8,850 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

3,856

Median for Pain Management: 951

Drug cost

$316,456

Median for Pain Management: $26,034

Branded share of claims

40.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 109 $60,856
Nucynta Tapentadol Hcl Brand 52 $51,145
Diclofenac Potassium Generic 27 $28,232
Linzess Linaclotide Brand 39 $25,906
Oxycontin Oxycodone Hcl Brand 40 $23,689
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 497 $12,552
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 372 $12,445
Buprenorphine Generic 54 $12,366
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 99 $11,942
Diclofenac Sodium Generic 21 $11,510

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$125,153

Of which drugs: $725

Medicare patients

138

Average age 70

Services billed

1,563

87 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 41%
Diabetes 36%
Ischemic heart disease 35%
Chronic kidney disease 28%
Heart failure 23%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 21 24 $111
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 149 $16
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 26 38 $11
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 15 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $104
$104 109 —
PROLATE
  • Forte Bio-Pharma LLC $61
$61 — —
Prialt
  • TerSera Therapeutics LLC $46
$46 — —
UBRELVY
  • AbbVie, Inc. $41
$41 — —
VYEPTI
  • Lundbeck LLC $40
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

390 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record